Flaharty Asset Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-5,110
Closed -$203K – 463
2023
Q3
$203K Hold
5,110
– – 0.03% 110
2023
Q2
$209K Hold
5,110
– – 0.04% 109
2023
Q1
$210K Hold
5,110
– – 0.04% 108
2022
Q4
$209K Buy
+5,110
New +$213K 0.04% 112

Other funds holding XPH

Flaharty Asset Management's XPH Position: Q4 2023 in Review

Flaharty Asset Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2023, closing a stake of 5,110 shares — an estimated $203K sold.

Flaharty Asset Management first reported a position in XPH in Q4 2022 and held it in 4 quarters. The position peaked at $210K in Q1 2023. 73 funds tracked by Wall St. Rank hold XPH as of Q4 2023.

  • Flaharty Asset Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
  • Flaharty Asset Management sold 5,110 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2023, an estimated $203K.
  • Flaharty Asset Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2022 and held it in 4 quarters.
  • Flaharty Asset Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $210K in Q1 2023.
  • 73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2023.

Based on Flaharty Asset Management's 13F filing for Q4 2023, filed 5 Feb 2024.